Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Found 24 results
Author Title [ Type(Asc)] Year
Filters: First Letter Of Last Name is Z  [Clear All Filters]
Journal Article
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..  2017.  Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..  2020.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..  2020.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..  2021.  Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al..  2021.  Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.
Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW.  2020.  Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.. Antibiotics (Basel). 9(8)
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2021.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2021.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell.
Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.  2013.  S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW.  2018.  Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.
Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR.  2013.  Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.
Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ.  1999.  Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.. Hepatology. 29(4):1070-3.
Agrawal M, Zhang W, Lukin D.  2019.  Intestinal Spirochetosis Resembles Inflammatory Bowel Disease in a Patient With HIV Infection.. Clin Gastroenterol Hepatol. 17(6):e60.
Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al..  2017.  IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)
Zhang N, Yantiss RK, Nam H-S, Chin Y, Zhou XKathy, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R.  2014.  ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.. Stem Cell Reports. 3(5):716-24.
Zhang N, Yantiss RK, Nam H-S, Chin Y, Zhou XKathy, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R.  2014.  ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.. Stem Cell Reports. 3(5):716-24.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al..  2015.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M.  2011.  Bone, inflammation, and inflammatory bowel disease.. Curr Osteoporos Rep. 9(4):251-7.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki MLynn, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J et al..  2021.  Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.. Inflamm Bowel Dis.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki MLynn, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J et al..  2021.  Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.. Inflamm Bowel Dis.
Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW.  2018.  5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.. J Antibiot (Tokyo). 71(11):950-961.